Hangzhou Tigermed Consulting Co., Ltd. (Tigermed) announced that its employee representative meeting elected Mr. Wu Hao as the employee director to the sixth session of the Board on 2 June 2026. The appointment will take effect upon shareholder approval of the entire sixth-session Board and will run through the full term of that session.
The Articles of Association stipulate that Tigermed’s Board comprises seven directors, including one employee representative. With the fifth-session Board nearing expiry, Wu’s election satisfies this structural requirement and finalises the proposed director slate for the sixth session.
Profile of the incoming employee director • Age: 58 • Current roles: executive director, co-president, and member of Tigermed’s strategy development committee (joined the Group in January 2020; appointed director in October 2021). • Industry experience: more than 17 years in pharmaceuticals, covering senior sales, marketing, and general management positions at Schering-Plough, Roche, Eisai China, SciClone International, and Meixin Insurance Broker (Shanghai). • External position: non-executive director of Frontage Holdings Corporation since 1 June 2022. • Education: bachelor’s degree in clinical medicine (Shanghai Jiao Tong University School of Medicine, 1992) and EMBA (China Europe International Business School, 2009).
Remuneration terms Tigermed has an employment contract with Wu; compensation levels are set by the Board with reference to the Group’s remuneration policy, his duties, and experience. He will not receive additional pay for serving as an employee director, and total remuneration will be disclosed in the Company’s annual report.
Compliance disclosures The Board confirmed that, aside from details stated above, Wu holds no other positions within the Group, no directorships in other listed companies over the past three years (except Frontage Holdings), no related-party connections with existing directors, management, or major shareholders, and no reportable share interests under Hong Kong’s Securities and Futures Ordinance.
Board composition after appointment Executive directors: Dr. Ye Xiaoping (Chairman), Ms. Cao Xiaochun, Mr. Wen Zengyu Employee director: Mr. Wu Hao Independent non-executive directors: Mr. Yuan Huagang, Ms. Liu Yuwen, Mr. Siu Paul Yu Hay
The company’s announcement states that no additional matters require disclosure under Listing Rule 13.51(2)(h)–(v).
Comments